St. Jude Releases New Cardiac Defibrillation Lead
The TVL-ADX lead uses a true bipolar configuration for precise sensing, an extendable/retractable helix for active fixation in the ventricle, and steroid elution for reduced inflammation and low chronic pacing thresholds.
"Given the enthusiastic reception that our ICDs have received among physicians, it is critically important for us to provide a full range of complementary lead types," said Daniel J. Starks, president and CEO of St. Jude Medical's Cardiac Rhythm Management Division. "With its active fixation, steroid-eluting capability, and true bipolar design, the TVL-ADX lead completes our lead product line by allowing us to offer a comprehensive portfolio of both bradycardia and tachycardia leads."
The new lead builds on proven technologies that St. Jude Medical employs in its Tendril DX cardiac pacing leads. "Implantable defibrillation technology has evolved very rapidly over the past several years, in part because we've adapted proven bradycardia pacing methodologies," according to Michael T. Rousseau, CRMD senior executive vice president of sales and marketing. "We're taking advantage of the considerable experience we've had with bradycardia pacing leads, making this new lead much easier to implant for the physician, and safer and more effective for the patient."